Fluorescent green dye helps surgeons reduce complications after surgery for people with soft tissue sarcoma
A team of researchers at Mayo Clinic has discovered that using fluorescent green dye combined with imaging during surgery for soft tissue sarcoma can help surgeons determine what tissue may be at risk of poor healing. This information allows surgeons to change the wound closure to reduce the risk of complications as the patient heals. Soft tissue sarcoma forms in tissues that connect, support and surround other body structures, including muscle, fat, blood vessels, nerves, tendons… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 24, 2023 Category: Databases & Libraries Source Type: news
FDA Approves First Therapy for Progressive Desmoid Tumors
(MedPage Today) -- The FDA approved the first treatment for adults with progressive desmoid tumors, a rare type of benign soft-tissue sarcoma.
The approval of oral nirogacestat (Ogsiveo) stipulates use in patients with progressive tumors that... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 28, 2023 Category: American Health Source Type: news
FDA approves first therapy for rare type of non-cancerous tumors
The U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. (Source: World Pharma News)
Source: World Pharma News - November 28, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors
The FDA approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Nirogacestat is a new molecular entity and the first drug to be approved for the treatment of patients with desmoid tumors, a subtype of soft tissue sarcomas. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 27, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Road to RSNA 2023: Molecular Imaging
This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. Notably, this is the first year a scientific session is being offered that covers advances in AI in nuclear medicine. Presentations on PET imaging in prostate cancer – an approach that is witnessing widespread adoption – include an array of studies on prostate-specific membrane antigen (PSMA)-based radiotrac...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 2023 Molecular Imaging Preview Source Type: news
FDG-PET reveals patterns in newly recognized fused in sarcoma proteinopathy
Wednesday, November 29 | 8:20 a.m.-8:30 a.m. | W1-SSNMMI05-3 | E350FDG-PET may help differentiate patients with fused in sarcoma (FUS), a newly recognized proteinopathy causing progressive dementia, from those with Alzheimer’s disease (AD) and frontotemporal dementia (FTD), according to this presentation.Proteinopathy is an umbrella term for distinct neurodegenerative disorders involving the accumulation of specific proteins in brain tissue.In a postmortem study, researchers analyzed FDG-PET imaging data from 28 AD (70.1 ± 9.1 years old), 10 FTD (67 ± 6.7 years old), and three FUS (51.6 ± 17 years old) patients compar...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Molecular Imaging Preview Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
CT radiomics help characterize retroperitoneal sarcomas
CT radiomics can help clinicians predict the histological type and grade of retroperitoneal sarcomas, a study published in the November issue of The Lancet Oncology has found.The results could have "important implications for improving diagnosis and risk stratification" of these cancers, wrote a team led by Amani Arthur, MD, of the Institute of Cancer Research in London, U.K."Our radiomics model to predict histological subtype and grade presents a conceptual advance and an opportunity for a change in personalized care for patients with retroperitoneal sarcoma," the group noted.Retroperitoneal sarcomas are large and comp...
Source: AuntMinnie.com Headlines - November 2, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Imaging Informatics Advanced Visualization Source Type: news
'I never thought he would die - I always had hope': Jeremy Hunt bravely opens up on his heartbreak after death of 53-year-old brother Charlie from ultra-rare cancer
EXCLUSIVE: Speaking at a fundraising event for Sarcoma UK, Jeremy Hunt paid tribute to families who used personal tragedies to strive for breakthroughs, vowing to do the same for Charlie. (Source: the Mail online | Health)
Source: the Mail online | Health - October 3, 2023 Category: Consumer Health News Source Type: news
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
THURSDAY, Sept. 7, 2023 -- The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the Sept. 7 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Pennsylvania Study Suggests Links Between Fracking and Asthma, Lymphoma in Children
[time-brightcove not-tgx=”true”]
(HARRISBURG, Pa.) — Children who lived closer to natural gas wells in heavily drilled western Pennsylvania were more likely to develop a relatively rare form of cancer, and nearby residents of all ages had an increased chance of severe asthma reactions, researchers said in reports released Tuesday evening.
The taxpayer-funded research by the University of Pittsburgh adds to a body of evidence suggesting links between the gas industry and certain health problems.
In the reports, the researchers found what they called significant associations between gas industry acti...
Source: TIME: Health - August 16, 2023 Category: Consumer Health News Authors: MARC LEVY / AP Tags: Uncategorized healthscienceclimate wire Source Type: news
Nutmeg co-founder Nick Hungerford dies aged 43, months after setting up charity
He was first diagnosed with Ewing sarcoma, a rare form of bone cancer in 2019 when he felt a pain in his right thigh, and had an operation to remove his femur. But at the end of 2021, the cancer returned and he revealed two weeks ago in The Telegraph that he had two or three months left to live.…#telegraph #smilenetwork (Source: Reuters: Health)
Source: Reuters: Health - July 11, 2023 Category: Consumer Health News Source Type: news
